Allyl isothiocyanates (AITC) have gained recognition in recent years as effective chemotherapeutic and epigenetic modulators. The chemopreventive properties and toxicological perspectives of AITCs from the last few decades were taken into account by a number of investigations. Their active therapeutic relevance was hindered by a number of factors, including instability under typical physiological conditions and low bioavailability due to low aqueous solubility. In this review, we highlighted the chemopreventive attributes of AITC in relation to its molecular mechanisms and metabolic fate for cancer. Moreover, we emphasized on investigational anticancer activities and various strategies for delivery of AITC in different types of cancer. Considering cellular interactions, we shed light on the toxicological properties of AITCs to address further issues regarding their assessment in therapeutic development. This review identifies knowledge gaps with various contemporary approaches involving most recent studies and may pave the way for a better understanding for the development of novel AITC therapeutics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11010-023-04697-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Surgery versus radiotherapy for older patients (aged≥65 years) with stage I-II laryngeal cancer: an investigational study from the SEER database.
Expert Rev Anticancer Ther
January 2025
Department of Radiology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.
Background: Currently, the choice between radiotherapy and surgery for treating older patients with early laryngeal cancer remains unclear. The aim of this retrospective study is to investigate the therapeutic patterns and survival outcomes for a cohort of older patients with early laryngeal cancer who received radiation therapy (RT) or surgery.
Methods: Clinical records of 1833 patients aged 65+ with stage I/II laryngeal cancer from the SEER registry (2010-2015) were assessed.
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production.
MAbs
December 2025
St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK.
Antibodies used for cancer therapy are monoclonal IgGs, but tumor-targeting IgE antibodies have shown enhanced effector cell potency against cancer in preclinical models. Research-grade recombinant IgE antibodies have been generated and studied for several decades. The recent Phase 1 clinical trial of the first-in-class MOv18 IgE, however, necessitated the inaugural process development and scaled manufacture of a recombinant IgE to clinical quality standards.
View Article and Find Full Text PDFRepurposing the Antihypertensive Agent Hydralazine As an Inhibitor of the Base Excision Repair Enzyme APE1.
Chem Res Toxicol
January 2025
University of Missouri, Department of Chemistry, 125 Chemistry Building, Columbia, Missouri 65211, United States.
Apurinic/apyrimidinic endonuclease 1 (APE1) is a central enzyme in the base excision repair (BER) pathway. APE1 catalyzes incision of the phosphodiester linkage on the 5'-side of apurinic/apyrimidinic (AP) sites during the repair of damaged nucleobases in cellular DNA. Inhibition of this enzyme can potentiate the action of DNA-damaging chemotherapeutic agents.
View Article and Find Full Text PDFTherapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database.
Expert Rev Anticancer Ther
December 2024
Department of Radiation Oncology, Shaoxing People' Hospital, Shaoxing, Zhejiang, China.
Background: The aim of this retrospective study is to explore therapeutic patterns and survival outcomes for a cohort of older patients with stage III-IVB inoperable oral squamous cell carcinoma (OCSCC) patients receiving radiation therapy (RT) with or without chemotherapy (CT).
Methods: This study conducted a retrospective review of 316 patients ≥ 65 aged years with stage III-IVB OCSCC from the Surveillance, Epidemiology, and End Results (SEER) registry (2010-2015). It compared RT alone ( = 109) with RT+CT ( = 207), utilizing Kaplan-Meier and Log-rank tests.
Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model.
J Ayurveda Integr Med
December 2024
Anti-Cancer Drug Screening Facility (ACDSF), Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai-410210, India; Kode Lab, Tumor Immunology & Immunotherapy (TII) Group, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai-410210, India; Homi Bhabha National Institute (HBNI), Training School Complex, Anushakti Nagar, Mumbai 400094, India. Electronic address:
Background: Xenografts in immunodeficient mice play a pivotal role in testing novel anti-cancer treatments. Xenograft models expedite the drug discovery process, offering a cost-effective alternative to conventional animal models and providing essential data for clinical trials. We have followed the approach described by the Developmental Therapeutics Program of the National Cancer Institute (NCI), USA to investigate the therapeutic responses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!